EndTB Clinical Trial Reveals Promising Paths for Tuberculosis Treatment

Explore promising breakthroughs in tuberculosis treatment unveiled at the EndTB clinical trial in Paris. This significant development, presented at the Global Conference on Lung Health, introduces new drug combinations and a potential game-changing molecule for severe cases. Launched in 2017, the trial, led by Médecins Sans Frontières and partners, aims to revolutionize tuberculosis care by showcasing three combinations with efficacy rates ranging from 85.2% to 90.4%. This ground-breaking research not only addresses drug-resistant tuberculosis but also sheds light on pediatric pharmacoresistance. The hope is to diversify treatment options and streamline the process with the introduction of already available combinations, potentially recommended by the World Health Organization by early 2024. Despite challenges related to the cost of certain components, this trial marks a transformative moment in tackling the historically neglected issue of tuberculosis, as highlighted by Lorenzo Guglielmetti, the project director at Médecins Sans Frontières.

Read the article »